Validation of the SGRQ-I derived from SGRQ

Thomas Skovhus Prior, Nils Hoyer, Saher Burhan Shaker, Jesper Rømhild Davidsen, Ole Hilberg, Haridarshan Patel, Elisabeth Bendstrup

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review


Introduction: Patients (pts) with idiopathic pulmonary fibrosis (IPF) have impaired health-related quality of life (HRQL). The St. George’s Respiratory Questionnaire (SGRQ) is also available in an IPF specific version (SGRQ-I). The aim of this study was to transform SGRQ into a derived version of SGRQ-I (SGRQ-Ider), to examine the validity of SGRQ-Ider and to compare SGRQ-Ider to the original SGRQ-I.Methods: SGRQ results were transformed into SGRQ-Ider in a cohort used to validate SGRQ-I. At baseline (BL) and 12 months, pts completed SGRQ, SGRQ-I, K-BILD, UCSD Shortness of Breath questionnaire, SF-36, and pulmonary function tests (PFT). Both cross-sectional and longitudinal validation were performed.Results: Questionnaires were completed by 150 pts at BL and 124 pts at 12 months. At BL, internal consistency was high in SGRQ-Ider (Cronbach’s α: 0.92). Good concurrent validity of SGRQ-Ider compared to SGRQ-I was demonstrated by a high intraclass correlation coefficient (ICC 2,1: 0.99), Bland Altman plot, moderate to strong correlations with other HRQL instruments (r=0.46–0.80) and weaker correlations with PFT (r=0.29–0.51). A high ICC (0.91) and a Bland Altman plot indicated good test-retest reliability. SGRQ-Ider was able to discriminate pts with different stages of disease based on PFT, oxygen therapy and GAP index. Responsiveness was demonstrated by moderate to strong correlations of change from BL in SGRQ-Ider with other HRQL instruments (r=0.55–0.95) and weaker correlations with PFT (r=0.24–0.48). Minimal clinically important difference after 12 months for improvement was 3.5 and 5.7 for deterioration.Conclusion: The SGRQ-Ider is valid both cross-sectionally and longitudinally and performs comparably to SGRQ-I. This was a collaborative study.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3750.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at (ERS member access only).
BogserieEuropean Respiratory Journal. Supplement
Udgave nummersuppl 65
Sider (fra-til)PA3750
StatusUdgivet - 5. sep. 2021
BegivenhedERS International Congress 2021 -
Varighed: 5. sep. 20218. sep. 2021


KonferenceERS International Congress 2021


Dyk ned i forskningsemnerne om 'Validation of the SGRQ-I derived from SGRQ'. Sammen danner de et unikt fingeraftryk.